Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289199 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL467974 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL20267799 | 1.00 | LMNA (0.38) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL238123 | 0.97 | — | — | |
| SCHEMBL95867 | 0.94 | — | — | |
| Water SCHEMBL29080231 | 0.90 | — | — | |
| SCHEMBL9193186 | 0.90 | SMN1; SMN2 (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| Chloroform SCHEMBL10841676 | 0.88 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL30569675 | 0.83 | — | — | |
| SCHEMBL30899237 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109564213-A | Detecting microbial wound infection | 西诺福有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| CN-103313599-B | Substituted 4- (arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD. (IN) | 2016-03-23 | — | — | CN | disclosed |
| EP-2424351-B1 | ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-10-21 | — | — | EP | disclosed |
| US-9090633-B2 | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| EP-2648509-B1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-04-29 | — | — | EP | disclosed |
| CN-102438449-B | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUT | 2014-06-18 | — | — | CN | disclosed |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-31 | — | — | US | disclosed |
| EP-2648509-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-10-16 | — | — | EP | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-0374789-A1 | 5- Aminoflavone derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-06-27 | — | — | EP | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
| EP-0343574-A1 | 4(1H)-quinolone derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
| EP-0337643-A2 | 6-Substituted acrylamido penicillanic acid derivatives, preparation and use | BEECHAM GROUP PLC (GB) | 1989-10-18 | — | — | EP | disclosed |
| EP-0335369-A2 | New anthracycline derivatives and processes for the preparation of the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1989-10-04 | — | — | EP | disclosed |
| EP-0183129-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-08-09 | — | — | EP | disclosed |
| EP-0183129-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4576961-A | Antibiotic heterocyclic oxygen compounds and use | Leo Pharmaceutical Products Ltd., A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1986-03-18 | — | — | US | disclosed |
| US-4329460-A | ANTICANCER AGENTS, ANTIVIRAL AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-05-11 | — | — | US | disclosed |
| US-4243586-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | SELENOI, VHL, DPYD | LMNA 3144/4885ALDH1A1 72/4885HSD17B10 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.